Diseases & Conditions
What’s new in diabetes drugs
Watch TV lately, and you may have noticed a slew of advertisements for two classes of diabetes drugs — GLP-1 receptor agonists and SGLT-2 inhibitors. Why are these medications being marketed so heavily? Sure, these new drugs add significant revenue to pharmaceutical companies. But they also offer health benefits beyond just keeping blood sugar levels controlled.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
About the Author
Matthew Solan, Executive Editor, Harvard Men's Health Watch
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
